Xiao-Fan Zhang, Hui-yun Wang, Sheng-Nan Zhao, Sheng-Nan Zhang, Feng-Lan Zhao and Qing-Guo Meng*

Crystal structure of (*E*)-2-(4-fluoro-3-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2*H*)-one, C₁₉H₁₄F₄O₂

Table 1: Data collection and handling.

Crystal:	Colourless block
Size:	0.13 × 0.12 × 0.11 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.13 mm ⁻¹
Diffraction, scan mode:	SuperNova,
$\theta_{\max}$, completeness:	25.5°, >99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	4729, 2802, 0.044
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 2165
$N(\text{param})_{\text{refined}}$:	227
Programs:	CrysAlis ^{PRO} [1], SHELX [2, 3]

<https://doi.org/10.1515/ncrs-2020-0448>

Received August 19, 2020; accepted September 23, 2020;

published online October 12, 2020

Abstract

C₁₉H₁₄F₄O₂, triclinic, $P\bar{1}$ (no. 2), $a = 8.1539(7)$ Å, $b = 8.8584(6)$ Å, $c = 11.8025(9)$ Å, $\alpha = 73.186(7)^\circ$, $\beta = 76.184(7)^\circ$, $\gamma = 69.512(7)^\circ$, $V = 755.39(11)$ Å³, $Z = 2$, $R_{\text{gt}}(F) = 0.0436$, $wR_{\text{ref}}(F^2) = 0.0965$, $T = 100$ K.

CCDC no.: 2016724

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
C1	0.2988 (2)	0.3305 (2)	0.48684 (17)	0.0133 (4)
C2	0.1929 (2)	0.3765 (2)	0.60124 (16)	0.0131 (4)
C3	0.0556 (2)	0.2900 (2)	0.66472 (17)	0.0154 (4)
H3A	−0.046055	0.336418	0.622769	0.018*
H3B	0.016091	0.308112	0.745352	0.018*
C4	0.1307 (2)	0.1037 (2)	0.67046 (17)	0.0162 (4)
H4A	0.218474	0.054304	0.724099	0.019*
H4B	0.036067	0.053469	0.702984	0.019*
C5	0.2153 (2)	−0.0733 (2)	0.51930 (18)	0.0173 (4)
H5	0.158663	−0.145004	0.574691	0.021*
C6	0.2978 (2)	−0.1103 (2)	0.40935 (18)	0.0187 (5)
H6	0.296071	−0.205323	0.391527	0.022*
C7	0.3833 (2)	−0.0044 (2)	0.32589 (17)	0.0164 (4)
C8	0.3838 (2)	0.1365 (2)	0.35360 (17)	0.0144 (4)
H8	0.441305	0.207256	0.297862	0.017*
C9	0.2997 (2)	0.1742 (2)	0.46359 (16)	0.0126 (4)
C10	0.2144 (2)	0.0675 (2)	0.54957 (17)	0.0144 (4)
C11	0.2330 (2)	0.4869 (2)	0.63856 (16)	0.0148 (4)
H11	0.328592	0.521549	0.592644	0.018*
C12	0.1455 (2)	0.5600 (2)	0.74244 (16)	0.0140 (4)
C13	0.2469 (2)	0.6008 (2)	0.80319 (17)	0.0146 (4)
H13	0.368496	0.577884	0.778324	0.017*
C14	0.1689 (2)	0.6745 (2)	0.89955 (16)	0.0125 (4)
C15	−0.0127 (2)	0.7119 (2)	0.93335 (17)	0.0152 (4)
C16	−0.1169 (2)	0.6785 (2)	0.87378 (17)	0.0160 (4)
H16	−0.239140	0.706603	0.896725	0.019*

*Corresponding author: Qing-Guo Meng, School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, PR China, E-mail: qinggmeng@163.com

Xiao-Fan Zhang, Sheng-Nan Zhao, Sheng-Nan Zhang and Feng-Lan Zhao, School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, PR China. <https://orcid.org/0000-0003-0674-2008> (X.-F. Zhang)

Hui-yun Wang, College of Pharmacy, Jining Medical University, Rizhao, 276826, PR China

Table 2: (continued)

Atom	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} */ <i>U</i> _{eq}
C17	−0.0369 (2)	0.6024 (2)	0.77918 (17)	0.0150 (4)
H17	−0.106861	0.578852	0.738910	0.018*
C18	0.2747 (2)	0.7185 (2)	0.96570 (17)	0.0165 (4)
C19	0.4475 (3)	−0.1562 (3)	0.17480 (19)	0.0276 (5)
H19A	0.496952	−0.260926	0.226263	0.041*
H19B	0.507533	−0.155696	0.094191	0.041*
H19C	0.323735	−0.138634	0.177394	0.041*
F1	−0.09011 (13)	0.78448 (14)	1.02701 (10)	0.0217 (3)
F2	0.26292 (14)	0.64104 (13)	1.08269 (9)	0.0209 (3)
F3	0.22247 (14)	0.88031 (13)	0.96210 (10)	0.0243 (3)
F4	0.44808 (13)	0.67637 (14)	0.92155 (10)	0.0219 (3)
O1	0.37797 (17)	0.42131 (16)	0.41329 (12)	0.0189 (3)
O2	0.46868 (17)	−0.02713 (17)	0.21432 (12)	0.0220 (3)

Source of material

7-Methoxy-1-tetralone and 4-fluoro-3-(trifluoromethyl) benzaldehyde were dissolved in 10 mL methanol. Sodium hydroxide (aqueous solution, 25%) was added to the mixture and stirred for 3 h at room temperature. The in process-control was monitored by silica gel thin layer chromatography (TLC, 254 nm). When 7-methoxy-1-tetralone was disappeared, the precipitate was filtered from the reaction mixture and dissolved with dichloromethane. The organic phase was washed respectively with deionized water and brine, dried over anhydrous sodium sulfate and condensed under vacuum. The crude product was purified by silica-gel column chromatography (petroleum ether: ethyl acetate = 10:1, v/v). Crystals were obtained under ambient conditions *via* solvent evaporation in the mixed solvents of dichloromethane and methanol (1:1, v/v) and drying under vacuo at 60 °C for 3 h.

Experimental details

The H atoms were placed in idealized positions and treated as riding on their parent atoms, with $d(\text{C-H}) = 0.97 \text{ \AA}$ (methylene), $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$, and $d(\text{C-H}) = 0.93 \text{ \AA}$ (aromatic), $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$.

Comment

Inflammation is a very common and important basic pathological process [4]. This process can result in the

excessive release of inflammatory mediators or cytokines such as NO, TNF- α , PGE₂, and interleukin (IL)-6 [5, 6]. When stimulated in the brain, the body defenses by producing inflammation. Microglia is the resident immune competent cells of the CNS [7, 8]. Activated microglia-mediated inflammatory responses play a key role in the pathological development of inflammatory neurodegenerative diseases in the central nervous system (CNS) [4, 7, 8]. Despite distinct embryonic origins, microglia and resident tissue macrophages are related. Monocyte-derived macrophages are classified into phenotypic subsets: M1, M2a, M2b and M2c. During inflammatory neurodegenerative diseases in CNS, the resident microglia become activated and polarized to a pro-inflammatory M1 phenotype [9]. It has been reported that the pro-inflammatory cytokines (tumor necrosis factor (TNF- α), interleukin (IL)-6, IL-1 β) secreted from M1 microglia can compromise BBB functions by activating the nuclear factor κ B (NF- κ B) signaling pathway [4, 10, 11], leading to BBB disruption. Concomitantly, the BBB disruption can promote glial activation then boosts CNS inflammation [12]. Moreover, activated microglia can produce reactive oxygen species (ROS), which may indirectly trigger neuroinflammation by activating NF- κ B [13]. Therefore, an NF- κ B inhibitor may be a perspective drug for the treatment of inflammatory CNS neurodegenerative diseases.

3,4-Dihydronaphthalen-1(2H)-one (DHN) derivatives with antitumor and anti-inflammatory activities have been investigated as novel modulators of allergic and inflammatory responses [14]. But DHN derivatives have rarely been developed as anti-neuroinflammatory drugs [4]. We designed a series of new benzylidene-substituted DHN derivatives and synthesized them through Claisen–Schmidt condensation reactions.

The crystal structure analysis revealed that **F1–2** crystallized in the triclinic space group $P\bar{1}$. The ORTEP diagram is presented in the Figure. There is only one drug molecule in the asymmetric unit. Compared to the C(2)=C(11) olefinic bonds, 4-fluoro-3-(trifluoromethyl) phenyl and carbonyl groups adopt the Stereochemistry [15, 16]. Because of the sterical effects 3,4-dihydrobenzo[*b*]oxepin-5(2H)-one, the 7-methoxyphenyl and 4-fluoro-3-(trifluoromethyl)phenyl groups are not coplanar with each other. This twisted configuration may increase interactions with bioactive molecules, for the purposes of creating more potent biological activity [17]. Bond lengths and angles are all in the expected ranges [18].

Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding information: This work was supported by Science and Technology Innovation Development Plan of Yantai (No. 2020XDRH105) and the National Natural Science Foundation of China (No. 81473104).

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Rigaku OD. *CrysAlis^{pro}*; Rigaku Oxford Diffraction Ltd: Yarnton, Oxfordshire, England, 2017.
2. Sheldrick G. M. A short history of *SHELX*. *Acta Crystallogr.* 2008, *A64*, 112–122.
3. Sheldrick G. M. Crystal structure refinement with *SHELXL*. *Acta Crystallogr.* 2015, *C71*, 3–8.
4. Sun Y., Gao Z. F., Wang C. H., Hou G. G. Synthesis, crystal structures and anti-inflammatory activity of fluorine-substituted 1,4,5,6-tetrahydrobenzo [h]quinazolin-2-amine derivatives. *Acta Crystallogr.* 2019, *C75*, 1157–1165.
5. Zhang J. Q., Zhang Q., Xu Y. R., Li H. X., Zhao F. L., Wang C. M., Liu Z., Liu P., Liu Y. N., Meng Q. G., Zhao F. Synthesis and in vitro anti-inflammatory activity of C20 epimeric ocotillol-type triterpenes and protopanaxadiol. *Planta Med.* 2019, *85*, 292–301.
6. Wang C. M., Liu J., Deng J. Q., Wang J. Z., Weng W. Z., Chu H. X., Meng Q. G. Advances in the chemistry, pharmacological diversity, and metabolism of 20(R)-ginseng saponins. *J. Ginseng Res.* 2020, *44*, 14–23.
7. Sun Y., Zhou Y. Q., Liu Y. K., Zhang H. Q., Hou G. G., Meng Q. G., Hou Y. Potential anti-neuroinflammatory NF-κB inhibitors based on 3,4-dihydronaphthalen-1(2H)-one derivatives. *J. Enzyme Inhib. Med. Chem.* 2020, *35*, 1631–1640.
8. Gao C. L., Hou G. G., Liu J., Ru T., Xu Y. Z., Zhao S. Y., Ye H., Zhang L. Y., Chen K. X., Guo Y. W., Pang T., Li X. W. Synthesis and target identification of benzoxepane derivatives as potential anti-neuroinflammatory agents for ischemic stroke. *Angew. Chem. Int. Ed.* 2020, *59*, 2429–2439.
9. Streit W. J., Xue Q. S., Tischer J., Bechmann I. Microglial pathology. *Acta Neuropathol. Commun.* 2014, *2*, 142.
10. Pisanu A., Lecca D., Mulas G., Wardas J., Simbula G., Spiga S., Carta A. R. Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTP mouse model of progressive Parkinson's disease. *Neurobiol. Dis.* 2014, *71*, 280–291.
11. Liu J., Xu Y. R., Yang J. J., Wang W. Z., Zhang J. Q., Zhang R. M., Meng Q. G. Discovery, semisynthesis, biological activities, and metabolism of ocotillol-type saponins. *J. Ginseng Res.* 2017, *41*, 373–378.
12. Hou Y., Ryu C. H., Park K. Y., Kim S. M., Jeong C. H., Jeun S. S. Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice. *Stem Cell Res. Ther.* 2013, *4*, 77.
13. Yang Y., Salayandia V. M., Thompson J. F., Yang L. Y., Estrada E. Y., Yang Y. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. *J. Neuroinflammation*, 2015, *12*, Article 26; <https://doi.org/10.1186/s12974-015-0245-4>.
14. Barlow J. W., Zhang T., Woods O., Byrne A. J., Walsh J. J. Novel mast cell-stabilising amine derivatives of 3,4-dihydronaphthalen-1(2H)-one and 6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one. *Med. Chem.* 2011, *7*, 213–223.
15. Li N., Xin W. Y., Yao B. R., Wang C. H., Cong W., Zhao F., Li H. J., Hou Y., Meng Q. G., Hou G. G. Novel dissymmetric 3,5-bis(aryliden)-4-piperidones as potential antitumor agents with biological evaluation *in vitro* and *in vivo*. *Eur. J. Med. Chem.* 2018, *147*, 21–33.
16. Yao B. R., Sun Y., Chen S. L., Suo H. D., Zhang Y. L., Wei H., Wang C. H., Zhao F., Cong W., Xin W. Y., Hou G. G. Dissymmetric pyridyl-substituted 3,5-bis(aryliden)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation. *Eur. J. Med. Chem.* 2019, *167*, 187–199.
17. Li N., Yao B. Y., Wang C. H., Meng Q. G., Hou G. G. Synthesis, crystal structure and activity evaluation of novel 3,4-dihydro-1-benzoxepin-5(2H)-one derivatives as protein-tyrosine kinase (PTK) inhibitors. *Acta Crystallogr.* 2017, *C73*, 1003–1009.
18. El-Sayed N. E., Almaneai N. M., Ghabbour H. A., Alafeefy A. M. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C₁₉H₁₈O₄, Z. *Kristallogr. NCS* 2017, *232*, 203–205.